Sector | Healthcare |
Industry | - |
Day Range | 6.02 | 6.30 |
52-Wk Range | - | - |
Last Close | 6.09 |
Mkt Cap (m) | 419.52 |
Dividend yield | - |
ISIN | US23257D1037 |
Volume | 667,261.00 |
Exchange Venue | NAS |
CymaBay Therapeutics Inc is an American biotechnology enterprise. Its product candidates include Arhalofenate, MBX-8025, and MBX-2982, which are meant to combat serious metabolic diseases.
Price/Earning | - |
Price/Book | 2.68 |
Price/Sales | - |
P/CF | - |
Rev Growth (3 year avg) | - |
EPS Growth (3 year avg) | - |
Operating Margin % | - |
Net Margin % | - |
Return on Equity | - |
Debt/Equity | - |
en 14/07/2020 |
en 31/12/2019 |
Please refer to the below issuer website for further documents.
USD | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
Revenue (m) | 0.00 | 0.00 | 10.00 | 0.00 | 0.00 | - |
Operating Income (m) | -25.90 | -25.59 | -21.33 | -72.51 | -103.08 | - |
Net Income (m) | -15.53 | -26.67 | -27.56 | -72.55 | -102.81 | - |
Basic EPS | -0.82 | -1.14 | -0.79 | -1.25 | -1.53 | - |
Avg. Diluted Shares Outstanding (m) | 18.92 | 23.45 | 34.90 | 57.84 | 67.03 | - |
USD | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
Current Assets (m) | 42.79 | 18.53 | 103.54 | 181.56 | 202.92 | - |
Non Current Assets (m) | 0.29 | 0.83 | 0.70 | 5.19 | 2.80 | - |
Total Assets (m) | 43.08 | 19.36 | 104.25 | 186.75 | 205.73 | - |
Current Liabilities (m) | 6.15 | 9.31 | 16.31 | 14.42 | 17.64 | - |
Total Liabilities (m) | - | - | - | - | - | - |
Total Equity (m) | 28.12 | 3.94 | 84.95 | 170.42 | 186.35 | - |
USD | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
Operating Cash Flows (m) | -23.32 | -23.35 | -19.63 | -54.94 | -97.91 | - |
Capital Expenditure (m) | - | -0.04 | -0.03 | -0.53 | -0.32 | - |